Cleerly
Cardiology Pharmaceuticals November 12, 2026
Adding anticoagulants to antiplatelet therapy after stroke has always meant trading clots for bleeds, but that’s changing thanks to Bayer’s asundexian (Sunharbo), which just became the first-ever FDA-approved Factor XIa inhibitor for secondary stroke prevention.
Structural Heart November 9, 2026
To TAVR or not to TAVR, that is the question central to the PROGRESS trial presented at TCT 2026, and its results suggest the answer might be the former for certain high-risk patients with moderate AS.
Cardiac Imaging November 6, 2026
Every week, my clinic sees very different kinds of hearts under the same word: "athlete."